Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Here’s why the Mesoblast (ASX:MSB) share price is getting smashed

The Mesoblast Limited (ASX: MSB) share price is being crunched. It’s down 16% after giving an update about its Novartis AG (SWX: NOVN) agreement.

Mesoblast describes itself as a global leader in allogeneic cellular medicines for inflammatory diseases.

Mesoblast’s update on the Novartis agreement

The ASX healthcare share said that it had been notified by Novartis that it has chosen to terminate the agreement with Mesoblast before it closed.

Mesoblast said that it remains highly focused on executing its short-term objective to bring remestemcel-L to market for patients with acute respiratory distress syndrome (ARDS) due to COVID-19.

The company noted the observed mortality reduction with remestemcel-L in patients aged under 65 in the completed COVID ARDS trial, despite having missed the primary endpoint, is considered by Mesoblast to be a sufficiently strong signal to support pursuing an emergency use authorisation, the most direct path to market.

Mesoblast is preparing to initiate a phase 3 trial that may support a COVID ARDS emergency use authorisation. Management called this trial as pivotal. A positive outcome could be good for the Mesoblast share price.

COVID-19 remains a chance for Mesoblast

The company said that COVID-19 is likely to remain a serious global problem and can remain a major commercial opportunity for Mesoblast, with a steady state of intensive care unit (ICU) ARDS patients irrespective of vaccines and anti-viral treatments.

Mesoblast said that variants including Omicron present a growing threat due to increased infectivity and immune evasion from vaccines and monoclonal antibodies, increasing the urgent need for therapeutics to prevent the likely high mortality of those progressing to ICU and ARDS.

Summary thoughts on Mesoblast and the share price

Mesoblast has put its shareholders through a lot of volatility over the last couple of years. But it seems to be steadily heading down at the moment.

I’m not an expert on Mesoblast or COVID treatments, but with the world being two years into the pandemic, it seems the chance of Mesoblast playing a substantial part has significantly reduced and continues to seem less likely.

There are other ASX growth shares in the healthcare space that I’d rather look at as opportunities.

If you’re looking to learn how to do your own ASX company valuations, take our free share valuation course, which takes you through 6 common share valuation techniques, step by step.

Or try our Beginner Shares Course if you’re just starting out. Both are free.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content